West Pharmaceutical Services, Inc. (WST) is poised for growth with strong demand for GLP-1 products. However, pricing challenges and tariff risks are concerns. WST stock has fallen 22.1% this year. The company has a market cap of $18.1 billion and expects earnings to grow by 8.4% over the next five years.

Key catalysts for WST include strength in GLP-1 related demand and expansion opportunities. The company’s Annex 1 projects in Europe are driving growth, and operational efficiency is being maintained. However, factors hurting the stock include margin pressure, pricing headwinds, and tariff-related risks that could impact performance in 2025.

WST has seen positive estimate revisions for 2025, with earnings expected to be $6.74 per share and revenues at $3.03 billion. Other top-ranked stocks in the medical industry include Medspace (MEDP), GE HealthCare Technologies (GEHC), and Inogen (INGN), each with their own growth projections and earnings surprises.

For the latest stock recommendations and analysis, experts have identified 7 elite stocks as the most likely for early price pops. These handpicked stocks have historically outperformed the market and are worth considering for potential gains. To access the full list and download the report, visit the link provided for more information on these top picks.

Read more at Nasdaq: Reasons to Add West Pharmaceutical Stock to Your Portfolio Now